Current developments in immunotherapy in the treatment of multiple myeloma

Monoclonal antibody therapy in multiple myeloma

(2017) C Touzeau et al.   LEUKEMIA

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells

(2017) Iulia Diaconu et al.   MOLECULAR THERAPY

Management of multiple myeloma in older adults: Gaining ground with geriatric assessment

(2017) Tanya M. Wildes et al.   Journal of Geriatric Oncology

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

(2017) Reed Friend et al.   Drug Design Development and Therapy

CARs in the Lead Against Multiple Myeloma

(2017) Maria Ormhøj et al.   Current Hematologic Malignancy Reports

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

(2017) Tatiana Pazina et al.   OncoImmunology

A new era of immune therapy in multiple myeloma

(2016) Y.-T. Tai et al.   BLOOD

Myeloma CARs are rolling into the clinical arena

(2016) M. Hudecek et al.   BLOOD

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

(2016) T. Plesner et al.   BLOOD

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma

(2016) María-Victoria Mateos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

(2016) Jesus Berdeja et al.   Clinical Lymphoma Myeloma & Leukemia

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy

(2016) Ulrike Mock et al.   CYTOTHERAPY

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?

(2016) Monika Engelhardt et al.   HAEMATOLOGICA

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores

(2016) M. Engelhardt et al.   HAEMATOLOGICA

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

(2016) Paulina J. Paszkiewicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

(2016) Marije B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

(2016) R Monjezi et al.   LEUKEMIA

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

(2016) Jo Caers et al.   ONCOLOGIST

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?

(2016) Monika Engelhardt et al.   HAEMATOLOGICA

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

(2016) E. Drent et al.   HAEMATOLOGICA

Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores

(2016) M. Engelhardt et al.   HAEMATOLOGICA

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

(2015) S. Walz et al.   BLOOD

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

(2015) N. W. C. J. van de Donk et al.   BLOOD

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

(2015) S Lonial et al.   LEUKEMIA

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

(2015) I S Nijhof et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive cellular therapy: A race to the finish line

(2015) Carl H. June et al.   Science Translational Medicine

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

(2015) Paul G Richardson et al.   Lancet Haematology

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Multiple Myeloma in the Older Adult: Better Prospects, More Challenges

(2014) Tanya M. Wildes et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

(2013) M. Casucci et al.   BLOOD

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

(2013) B A Walker et al.   LEUKEMIA

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

(2013) Alberto L Horenstein et al.   OncoImmunology

Engineered T cells for anti-cancer therapy

(2012) Cameron J Turtle et al.   CURRENT OPINION IN IMMUNOLOGY

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

(2012) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

(2011) N W C J van de Donk et al.   LEUKEMIA

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

(2011) M S van der Veer et al.   Blood Cancer Journal

CD138 shedding in plasma cell myeloma

(2010) George Grigoriadis et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Adhesion molecules—The lifelines of multiple myeloma cells

(2010) Ben-Zion Katz   SEMINARS IN CANCER BIOLOGY

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

CD38 at the junction between prognostic marker and therapeutic target

(2008) Silvia Deaglio et al.   TRENDS IN MOLECULAR MEDICINE